Allogeneic hematopoietic cell transplantation ...
Document type :
Article dans une revue scientifique: Article original
PMID :
Permalink :
Title :
Allogeneic hematopoietic cell transplantation is equally effective in secondary acute lymphoblastic leukemia (ALL) compared to de-novo ALL-a report from the EBMT registry.
Author(s) :
Sadowska-Klasa, A. [Auteur]
Zaucha, J. M. [Auteur]
Labopin, M. [Auteur]
Sorbonne Université [SU]
Bourhis, J. H. [Auteur]
Institut Gustave Roussy [IGR]
Blaise, D. [Auteur]
Institut Paoli-Calmettes [IPC]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Salmenniemi, U. [Auteur]
Passweg, J. [Auteur]
Fegueux, N. [Auteur]
Hôpital Lapeyronie [CHU Montpellier]
Schroeder, T. [Auteur]
Giebel, S. [Auteur]
Brissot, E. [Auteur]
Sorbonne Université [SU]
Ciceri, F. [Auteur]
Mohty, M. [Auteur]
Sorbonne Université [SU]
Zaucha, J. M. [Auteur]
Labopin, M. [Auteur]
Sorbonne Université [SU]
Bourhis, J. H. [Auteur]
Institut Gustave Roussy [IGR]
Blaise, D. [Auteur]
Institut Paoli-Calmettes [IPC]
Yakoub-Agha, Ibrahim [Auteur]

Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Salmenniemi, U. [Auteur]
Passweg, J. [Auteur]
Fegueux, N. [Auteur]
Hôpital Lapeyronie [CHU Montpellier]
Schroeder, T. [Auteur]
Giebel, S. [Auteur]
Brissot, E. [Auteur]
Sorbonne Université [SU]
Ciceri, F. [Auteur]
Mohty, M. [Auteur]
Sorbonne Université [SU]
Journal title :
Bone Marrow Transplantation
Abbreviated title :
Bone Marrow Transplant
Volume number :
59
Pages :
387–394
Publication date :
2024-03
ISSN :
1476-5365
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Secondary acute lymphoblastic leukemia (s-ALL) comprises up to 10% of ALL patients. However, data regarding s-ALL outcomes is limited. To answer what is the role of allogeneic hematopoietic cell transplantation (HCT) in ...
Show more >Secondary acute lymphoblastic leukemia (s-ALL) comprises up to 10% of ALL patients. However, data regarding s-ALL outcomes is limited. To answer what is the role of allogeneic hematopoietic cell transplantation (HCT) in s-ALL, a matched-pair analysis in a 1:2 ratio was conducted to compare outcomes between s-ALL and de novo ALL (dn-ALL) patients reported between 2000–2021 to the European Society for Blood and Marrow Transplantation registry. Among 9720 ALL patients, 351 (3.6%) were s-ALL, of which 80 were in first complete remission (CR1) with a known precedent primary diagnosis 58.8% solid tumor (ST), 41.2% hematological diseases (HD). The estimated 2-year relapse incidence (RI) was 19.1% (95%CI: 11–28.9), leukemia-free survival (LFS) 52.1% (95%CI: 39.6–63.2), non-relapse mortality (NRM) 28.8% (95%CI: 18.4–40), GvHD-free, relapse-free survival (GRFS) 39.4% (95%CI: 27.8–50.7), and overall survival (OS) 60.8% (95%CI: 47.9–71.4), and did not differ between ST and HD patients. In a matched-pair analysis, there was no difference in RI, GRFS, NRM, LFS, or OS between s-ALL and dn-ALL except for a higher incidence of chronic GvHD (51.9% vs. 31.4%) in s-ALL. To conclude, patients with s-ALL who received HCT in CR1 have comparable outcomes to patients with dn-ALL.Show less >
Show more >Secondary acute lymphoblastic leukemia (s-ALL) comprises up to 10% of ALL patients. However, data regarding s-ALL outcomes is limited. To answer what is the role of allogeneic hematopoietic cell transplantation (HCT) in s-ALL, a matched-pair analysis in a 1:2 ratio was conducted to compare outcomes between s-ALL and de novo ALL (dn-ALL) patients reported between 2000–2021 to the European Society for Blood and Marrow Transplantation registry. Among 9720 ALL patients, 351 (3.6%) were s-ALL, of which 80 were in first complete remission (CR1) with a known precedent primary diagnosis 58.8% solid tumor (ST), 41.2% hematological diseases (HD). The estimated 2-year relapse incidence (RI) was 19.1% (95%CI: 11–28.9), leukemia-free survival (LFS) 52.1% (95%CI: 39.6–63.2), non-relapse mortality (NRM) 28.8% (95%CI: 18.4–40), GvHD-free, relapse-free survival (GRFS) 39.4% (95%CI: 27.8–50.7), and overall survival (OS) 60.8% (95%CI: 47.9–71.4), and did not differ between ST and HD patients. In a matched-pair analysis, there was no difference in RI, GRFS, NRM, LFS, or OS between s-ALL and dn-ALL except for a higher incidence of chronic GvHD (51.9% vs. 31.4%) in s-ALL. To conclude, patients with s-ALL who received HCT in CR1 have comparable outcomes to patients with dn-ALL.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
Université de Lille
Inserm
CHU Lille
Inserm
CHU Lille
Submission date :
2024-02-06T22:11:35Z
2024-08-19T11:04:35Z
2024-08-19T11:04:35Z